Sequential combination of anti-PD-1 antibody and PEG-IFNα in chronic hepatitis B patients: correlates of HBsAg loss with enhanced T-cell responses. (PubMed, Emerg Microbes Infect) - Sep 26, 2026 - P=N/A | "The patients continued background NA therapy and received αPD-1 (sintilimab) for up to 24 weeks; PEG-IFNα was added at week 12 if HBsAg decline was <1 log10 IU/mL...Exploratory analyses showed that week-3 IL-10 was positively associated with early ALT elevation and subsequent HBsAg decline. These findings support further evaluation of response-guided sequential immunotherapy strategies in larger, controlled, and well-characterized cohorts.Trial registration: ClinicalTrials.gov identifier: NCT06457477.."
Journal • Hepatitis B • Infectious Disease • Inflammation • IFNA1 • IFNG • IL10 • IL2
|
|
Chao Zhang; Fu-Sheng Wang; Hongmin Wang; Junliang Fu; Kaili Wang; Qing Wang; Ruonan Xu; Sa Lv; Shanquan Liu; Shengxian Yang; Shuangsuo Dang; Xiaoning Zhang; Xiaoying Li; Xin Zhang; Xing Fan; Yaping Li
|